Cargando…
Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment
There are limited data on the safety and efficacy of immunotherapy for patients with advanced pancreatic cancer (APC). A meta-analysis of single-arm trials is proposed to assess the efficacy and safety of immunotherapy for APC. Eighteen relevant studies involving 527 patients were identified. The po...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351583/ https://www.ncbi.nlm.nih.gov/pubmed/27992378 http://dx.doi.org/10.18632/oncotarget.13968 |
_version_ | 1782514784793526272 |
---|---|
author | Zhang, Bin Dong, Yuhao Liu, Jing Lian, Zhouyang Liang, Long Chen, Wenbo Luo, Xiaoning Pei, Shufang Mo, Xiaokai Zhang, Lu Huang, Wenhui Ouyang, Fusheng Guo, Baoliang Liang, Changhong Zhang, Shuixing |
author_facet | Zhang, Bin Dong, Yuhao Liu, Jing Lian, Zhouyang Liang, Long Chen, Wenbo Luo, Xiaoning Pei, Shufang Mo, Xiaokai Zhang, Lu Huang, Wenhui Ouyang, Fusheng Guo, Baoliang Liang, Changhong Zhang, Shuixing |
author_sort | Zhang, Bin |
collection | PubMed |
description | There are limited data on the safety and efficacy of immunotherapy for patients with advanced pancreatic cancer (APC). A meta-analysis of single-arm trials is proposed to assess the efficacy and safety of immunotherapy for APC. Eighteen relevant studies involving 527 patients were identified. The pooled disease control rate (DCR), overall survival (OS), progression free survival (PFS), and 1-year survival rate were estimated as 59.32%, 7.90 months, 4.25 months, and 30.12%, respectively. Subgroup analysis showed that the pooled OS, PFS, and 1-year survival rate were significantly higher for autologous activated lymphocyte therapy compared with peptide-based vaccine therapy (OS: 8.28 months vs. 7.40 months; PFS: 6.04 months vs. 3.86 months; 1-year survival rate: 37.17% vs. 19.74%). Another subgroup analysis demonstrated that the pooled endpoints were estimated as obviously higher for immunotherapy plus chemotherapy compared with immunotherapy alone (DCR: 62.51% vs. 47.63%; OS: 8.67 months vs. 4.91 months; PFS: 4.91 months vs. 3.34 months; 1-year survival rate: 32.32% vs. 21.43%). Of the included trials, seven trials reported no treatment related adverse events , five trials reported (16.6 3.9) % grade 3 adverse events and no grade 4 adverse events. In conclusion, immunotherapy is safe and effective in the treatment of APC. |
format | Online Article Text |
id | pubmed-5351583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53515832017-04-13 Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment Zhang, Bin Dong, Yuhao Liu, Jing Lian, Zhouyang Liang, Long Chen, Wenbo Luo, Xiaoning Pei, Shufang Mo, Xiaokai Zhang, Lu Huang, Wenhui Ouyang, Fusheng Guo, Baoliang Liang, Changhong Zhang, Shuixing Oncotarget Research Paper There are limited data on the safety and efficacy of immunotherapy for patients with advanced pancreatic cancer (APC). A meta-analysis of single-arm trials is proposed to assess the efficacy and safety of immunotherapy for APC. Eighteen relevant studies involving 527 patients were identified. The pooled disease control rate (DCR), overall survival (OS), progression free survival (PFS), and 1-year survival rate were estimated as 59.32%, 7.90 months, 4.25 months, and 30.12%, respectively. Subgroup analysis showed that the pooled OS, PFS, and 1-year survival rate were significantly higher for autologous activated lymphocyte therapy compared with peptide-based vaccine therapy (OS: 8.28 months vs. 7.40 months; PFS: 6.04 months vs. 3.86 months; 1-year survival rate: 37.17% vs. 19.74%). Another subgroup analysis demonstrated that the pooled endpoints were estimated as obviously higher for immunotherapy plus chemotherapy compared with immunotherapy alone (DCR: 62.51% vs. 47.63%; OS: 8.67 months vs. 4.91 months; PFS: 4.91 months vs. 3.34 months; 1-year survival rate: 32.32% vs. 21.43%). Of the included trials, seven trials reported no treatment related adverse events , five trials reported (16.6 3.9) % grade 3 adverse events and no grade 4 adverse events. In conclusion, immunotherapy is safe and effective in the treatment of APC. Impact Journals LLC 2016-12-15 /pmc/articles/PMC5351583/ /pubmed/27992378 http://dx.doi.org/10.18632/oncotarget.13968 Text en Copyright: © 2017 Zhang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Zhang, Bin Dong, Yuhao Liu, Jing Lian, Zhouyang Liang, Long Chen, Wenbo Luo, Xiaoning Pei, Shufang Mo, Xiaokai Zhang, Lu Huang, Wenhui Ouyang, Fusheng Guo, Baoliang Liang, Changhong Zhang, Shuixing Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment |
title | Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment |
title_full | Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment |
title_fullStr | Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment |
title_full_unstemmed | Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment |
title_short | Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment |
title_sort | immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351583/ https://www.ncbi.nlm.nih.gov/pubmed/27992378 http://dx.doi.org/10.18632/oncotarget.13968 |
work_keys_str_mv | AT zhangbin immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT dongyuhao immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT liujing immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT lianzhouyang immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT lianglong immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT chenwenbo immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT luoxiaoning immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT peishufang immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT moxiaokai immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT zhanglu immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT huangwenhui immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT ouyangfusheng immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT guobaoliang immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT liangchanghong immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment AT zhangshuixing immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment |